Secondary Logo

Journal Logo

Original Articles

Associations of adiponectin and leptin with brain natriuretic peptide in African Americans

the Jackson Heart Study

Horbal, Steven R.a; Hall, Michael E.b; Dinh, Paul C.a; Smiley, Abbasa; Musani, Solomon K.b; Liu, Jiankangc; Taylor, Herman A.d; Fox, Ervin R.b; Bidulescu, Aureliana

Author Information
Cardiovascular Endocrinology & Metabolism: June 2020 - Volume 9 - Issue 2 - p 49-55
doi: 10.1097/XCE.0000000000000198
  • Free

Abstract

Introduction

Adiponectin and leptin are hormones that modulate different obesity-related processes. Adiponectin is a 30-kDa peptide hormone secreted by adipose tissue that mediates insulin sensitivity in peripheral tissues and has protective effects against atherosclerosis [1,2]. Leptin is also secreted by adipose tissue and works via the central nervous system to mediate energy balance regulation, reduce appetite and stimulate metabolic processes [3,4].

Heart failure is a multifactorial condition that results in excessive volume overload, increased sympathetic activity, circulation redistribution and result in changes to myocardial integrity and possible cardiac dysfunction [5]. Brain natriuretic peptide (BNP) is excreted in response to volume expansion and pressure overload, and is a useful biomarker of left ventricular diastolic and systolic dysfunction [6]. Allison et al. demonstrated higher levels of adiponectin, but not leptin, were significantly associated with higher levels of N-Terminus (NT)-proBNP (the active fraction of BNP) in a multiethnic cohort, and gender stratified analyses showed higher associations in men [7]. Elevated levels of leptin have been observed in patients with dilated cardiomyopathy, inferring leptin to be a putative biomarker for disease progression [8,9]. Leptin’s actions on blood pressure and heart rate are apparent, and leptin has beneficial actions on cardiac metabolism and lipid accumulation [9].

Multiple studies have demonstrated racial/ethnic differences regarding BNP distributions and stress the importance of racial/ethnic-specific thresholds [10,11]. African-American men and women have been shown to have ~2–3 times higher prevalence of left ventricular hypertrophy (LVH) than whites and will subsequently have a much larger proportional influence of heart failure-related risk factors [12].

Quantifying associations of adiponectin and leptin with BNP may provide a mechanism for the relationship between obesity and heart failure. We hypothesize a reciprocal relationship of adiponectin and leptin with BNP. Specifically, an inverse association between adiponectin and BNP, while a direct association with leptin and BNP. Identification of the magnitude of African-American-specific associations with adipokines and BNP may provide evidence for magnitudes of racial/ethnic burden. Identification of specific associations of adipokines and BNP should provide information on racial/ethnic mechanistic differences, and possible diagnostic tools.

Methods

The Jackson Heart Study (JHS) is a single-site, prospective cohort study devoted to the study of African-American-specific risk factors, as well as etiology of heart disease. An overview of the study, design and data collection, and recruitment are published elsewhere [13–15]. Annual follow-up and cohort surveillance are ongoing. Documented consent was obtained from each participant at the inception of the study, and the study was approved by the participating JHS institutions: Jackson State University, Tougaloo College, and The University of Mississippi Medical Center.

Our sample included 3738 of the 5306 eligible participants, participants with measured biomarkers levels. Exclusion was performed for missing data of cardiovascular variables, prevalent cardiovascular disease (CVD), as well as prevalent coronary heart disease.

Covariates

Initial physical examination, anthropometric variables, medical history, and medication use were ascertained at JHS Exam I (2000–2004). Biological specimens were collected in the majority of participants. BMI was calculated by dividing body weight in kilograms by height in meters squared. Blood pressure measurement was based on the average of two 1-min blood pressure measurements, separated by a 1-min rest. Smoking status was self-reported in the baseline assessment. Insulin resistance was calculated using the homeostasis model assessment for insulin resistance [16]. Standard laboratory techniques were used to describe lipid variables, fasting plasma glucose, and creatinine. Pharmacological treatment was ascertained at the baseline examination.

Venous blood samples were drawn at baseline from patients that had fasted for at least 8 hours. Serum was stored at −80°C in the JHS central repository in Minneapolis, MN, USA. The inter-assay coefficient of variation was 8.8% and no biological degradation was apparent [17]. Detailed adiponectin and leptin methodologies were described elsewhere [15,17–19].

Cardiovascular risk factor-related measurements were ascertained during JHS exam 1 through standard procedures and questionnaires. Four experienced sonographers performed echocardiograms, while reading was performed by an experienced cardiologist with level III training in echocardiography [20]. Left ventricular mass (LVM) was calculated using the American Society of Echocardiography corrected formula by Devereux and is described elsewhere [20,21].

Missing data reduced the sample sizes for respective echocardiographic measurements. Further reductions to various measurements occurred due to agreement between the presence of adiponectin, leptin, and echocardiographic measurements. All sample sizes are noted in their respective tables due to variations in available data.

Plasma BNP measurement is described elsewhere [22]. Briefly, the JHS sample used a chemiluminescent immunoassay. The coefficient of variation was measured at three concentrations: level 1 (CV = 4.2%), level 2 (CV = 3.1%), level 3 (3.4%) and the minimal detectable concentration of BNP in the assay was 2.0 pg/mL.

The study protocol for the ascertainment of the adiponectin sampling was approved by the Morehouse School of Medicine Institutional Review Board. Venous blood measurements of adiponectin and leptin were described elsewhere [17].

Statistical analysis

For each demographic characteristic, echocardiographic measure and biomarker, Student’s t-test was performed on continuous variables and chi-square tests were performed on categorical variables comparing measurements among men and women.

Multiple linear regression was used to test the associations between BNP and adiponectin or leptin, controlling for pertinent confounders through calculations of β-coefficients, P-values and their respective 95% confidence intervals (CIs). Model 1 included standard cardiovascular risk factors including age, gender, BMI, eGFR, diabetes, and hypertension. Model 2 included all covariates in model 1 as well as the echocardiographic measures of LVM and ejection fraction. Model 3 included those in model 1 plus relevant cardiovascular biomarkers, including aldosterone, renin, and the addition of adiponectin or leptin. Effect modification was assessed through the addition of an interaction term to the linear model between gender and adiponectin or leptin.

Multiple adjusted logistic regression was used to report the odds ratios (OR) reflecting the association of adiponectin or leptin with BNP. The covariates adjusted for were identical to those implemented in the multiple linear regression models. Adiponectin, leptin, and BNP were discretized for logistic analysis. Adiponectin and leptin were both divided into quartiles, the cut-point was decided a priori to be 75%. The upper 25% was compared to the lower 75%. BNP was discretized based on the clinical cut-point of 100 pg/mL.

Analyses were performed using R version 3.5.3 [23]. Figure 1 was generated with the ‘ggplot2’ package [24].

Fig. 1
Fig. 1:
Multivariate adjusted associations of adipokines with brain natriuretic peptide in men and women.

Results

Descriptive statistics

Table 1 reports the descriptive statistics of this JHS sample, including demographic, clinical, biomarker, and echocardiographic measures. Among the 3738 individuals in our sample, 1362 (36%) were men, and 2376 (64%) were women. Men and women had statistically significant different means among most variables in this study. The mean (SD) age of men was 53 (13) and the mean age of women was 54 (13) (P < 0.01). Mean (SD) BMI was 30 (6) in men and 33 (8) in women (P < 0.01). Mean (SD) BNP in men 14 (34) pg/mL and 16 (28) in women and were not statistically different (P = 0.15).

Table 1
Table 1:
Descriptive statistics for Jackson Heart Study sample

Adiponectin

Table 2 reports the main effects of the associations of adiponectin and leptin with BNP, as gender significantly modified the relation between adiponectin and BNP at α = 0.10 (β = 0.11, P = 0.06) the analysis was stratified by gender. In men (Table 3), a direct relation with adiponectin and BNP was observed in all three models: model 1 [β = 0.47 (95% CI, 0.38–0.55)], model 2 [β = 0.45 (95% CI, 0.34–0.55)], and model 3 (β = 0.41 (95% CI, 0.26–0.57)]. Among women (Table 4), a direct relation with adiponectin and BNP was observed in all three models, model 1 [β = 0.38 (95% CI, 0.31–0.46), model 2 [β = 0.38 (95% CI, 0.38–0.47), and model 3 [β = 0.32 (95% CI, 0.18–0.44)]. Figure 1 depicts the beta coefficients and CIs for the associations of adiponectin and BNP in all three models.

Table 2
Table 2:
Associations of adipokines with brain natriuretic peptide in men and women
Table 3
Table 3:
Associations of adipokines with brain natriuretic peptide in men
Table 4
Table 4:
Associations of adipokines with brain natriuretic peptide in women

Table 5 reports the odds ratios of BNP levels being higher than 100 pg/mL among participants in the highest quartile compared to the lower three quartiles. In the parsimonious model, participants in the highest quartile were 1.70 times more likely to have an elevated BNP compared to participants in the lower three quartiles (95% CI, 1.07–2.72). After the model was adjusted for left ventricular mass and ejection fraction, the relative odds of elevated BNP increased to 2.08 (95% CI, 1.01–4.32). The association was attenuated after adjustment for common cardiovascular-related biomarkers.

Table 5
Table 5:
Odds ratios of adipokines with brain natriuretic peptide

Leptin

Gender did not significantly modify the relation between leptin and BNP. Table 2 includes the main effects of leptin with BNP; an inverse relation of leptin to BNP was observed in model 1 and model 2: model 1 [β = −0.14 (95% CI, −0.24 to −0.03)], [β = −0.17 (95% CI, −0.30 to −0.04)]. Adjustment of aldosterone and renin attenuated the magnitude and significance of the association: Model 3 [β = −0.16 (95% CI, −0.33 to 0.01)]. The coefficients for the effect of leptin on BNP did not differ across gender and are reported in Tables 3 and 4. Figure 1 depicts the beta coefficients and CIs for the associations of Leptin and BNP in all three multivariate-adjusted models.

Table 5 reports the odds ratios of upper quartile to lower three quartiles of leptin; no association was found to be statistically significant.

Discussion

In this cross-sectional analysis, differential associations of leptin and adiponectin on BNP were observed among participants of the JHS. Adiponectin was directly associated with BNP while leptin was inversely associated with BNP. The associations were found to be statistically significant after adjusting for standard demographic and echocardiographic variables. The relationship with leptin and BNP was attenuated after the addition of the renin–angiotensin–aldosterone system (RAAS)-related variables aldosterone and renin.

Our finding of the differential association of adiponectin and leptin with BNP is contrary to our initial hypothesis. In vivo, adiponectin and leptin are consistently reported to be inversely correlated and a differential association of adiponectin and leptin has been observed with increasing obesity [25]. Adiponectin is relatively abundant in healthy individuals and reduced in obese participants, and insulin-resistant hypertensive subjects [26,27].

The direct association of adiponectin and BNP has been consistently reported in observational studies [28,29]. Cross-sectional analyses have reported positive correlations of adiponectin and BNP in noncachectic patients with systolic heart failure [30]. Increased levels of adiponectin were associated with elevated BNP levels and LVH in hemodialysis patients with type 2 diabetes mellitus [31]. A prospective cohort of 5574 men and women without heart failure at baseline also found a direct association between plasma adiponectin and NT-proBNP [32]. The current literature suggests a compensatory mechanism between adiponectin, BNP, and congestive heart failure attributed to pathophysiological stress. Release of BNP in response to ventricular dysfunction promotes the expression of adiponectin for its protective effects. Adiponectin signaling dysregulation, that is, ‘adiponectin resistance’, may also lead to sustained-elevated levels of adiponectin [17].

We observed an inverse association of leptin and BNP levels in men and women. This relationship was present after adjustment for measures of left ventricular geometry and function (left ventricular mass and ejection fraction) but attenuated after the addition of RAAS hormones (aldosterone and renin). Thus, RAAS-related hormones explain similar variance to leptin and BNP and may confound the association of leptin and BNP. Natriuretic peptides have been identified as vasodilators and suppression of RAAS, and increase renal blood flow [33]. Leptin has been associated with higher blood pressure levels, the prevalence of hypertension, as well as activation of RAAS [33,34]. While similar results in the literature are sparse, a study of adiponectin and leptin as prognostic indicators of pulmonary arterial hypertension found leptin to be associated with lower NT-proBNP [35]. The sympathetic nervous system and the RAAS have independent mechanism for progression of ventricular remodeling and different etiological pathways [36]. The three traditional criteria for confounding, the exposure relating to outcome, the confounder being a risk factor for the outcome and the absence of the confounder on the causal pathway are thereby met, providing for the confounding of RAAS on the leptin-BNP pathway.

We hypothesized consistent results to those of Allison et al. [7], who utilized data from the Multi-Ethnic Study of Atherosclerosis (MESA). Both studies report effect modification of adiponectin and BNP levels by gender. We observed consistently stronger associations of adiponectin concentration with BNP levels in men. Unlike the analysis performed by Allison et al., leptin was found to be significant prior to the adjustment for related hormones.

Average measurements of leptin remained consistent among NT-proBNP defined quartiles of MESA participants (19.5–20.8 ng/mL) while this JHS sample had more variability [Leptin in men 11.32 (SD 1.45), women 37.85 (SD 24.74)]. It is possible that differences among adiponectin, leptin, and BNP between the two cohorts could be explained by cohort makeup or selection biases. The most apparent difference between the two studies may rely on the cohort makeup. JHS is a community sample of African-American participants in Jackson, Mississippi, while MESA is multiethnic (28% White, 22% African-American, 22% Hispanic, and 12% Chinese) from six regions around the USA (North Carolina, New York, Maryland, Minnesota, Illinois, and California). Obesity and blood pressure values are higher in the base JHS cohort. These imbalances may explain some of the differences between leptin and BNP levels across both cohorts. Additionally, JHS measured BNP, while MESA measured NT-proBNP. While there may not be complete harmonization among the measurement, the two peptides have comparable diagnostic performance [37].

Strengths and limitations

Our study was conducted with participants from the JHS, the largest community-based sample of African Americans, which implements high-quality data collection techniques. To limit bias, we excluded participants with prevalent CVD or missing echocardiographic measurements, which may limit the generalizability of the study. Our study is cross-sectional, and thus we cannot characterize further this complex interrelationship of adiponectin, leptin, and BNP with renin–angiotensin–aldosterone system. Measurements of biomarkers were limited to one time-point. It is also worth noting that this population has a high frequency of participants using antihypertensive medication, which may be suppressing BNP levels and attenuating the sample level associations. Finally, researchers have suggested that the different oligomers of adiponectin (low, medium, and high molecular weight) may exert distinct actions on specific target tissues. The ability to stratify or control for these differential effects is currently limited due to a lack of JHS measurements as well as current sample size restrictions. Such analyses should be considered in the future.

In conclusion, we consistently observed different linear relationships of adiponectin and leptin with BNP, and adiponectin was linearly associated with BNP. Odds of elevated BNP in participants with elevated adiponectin levels were observed in multivariate-adjusted models. These relationships were maintained after the addition of left ventricular geometry and function, but confounded by the addition of RAAS-related hormones, renin, and aldosterone. These findings provide evidence towards the paradoxical relationship between adiponectin and plasma BNP, possibly through adiponectin resistance.

Acknowledgements

The Jackson Heart Study is supported and conducted in collaboration with Jackson State University (N01-HC-95170), University of Mississippi Medical Center (N01-HC-95171), and Tougaloo College (N01-HC-95172) NIH contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Center on Minority Health and Health Disparities (NCMHD) with additional support from NHLBI contract HL076784 and the National Institute of Aging (AG028321).

An early iteration of this research was presented at the American Heart Association’s Epidemiology, Prevention/Lifestyle, and Cardiometabolic Health 2016 Scientific Sessions

This study was partially supported by a sub-award of PHS Award UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources (NCRR) to the last author (A.B.) who was also supported with funds from the NIH grant UH1 HL073461 provided by the National Heart, Lung and Blood Institute and by the NIH grants U54 RR026137 and P20 RR11104 from NCRR.

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the US Department of Health and Human Services.

Conflicts of interest

There are no conflicts of interest.

References

1. Wiecek A, Adamczak M, Chudek J.. Adiponectin – an adipokine with unique metabolic properties. Nephrol Dial Transplant. 2007; 22:981–988
2. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K.. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116:1784–1792
3. Allison MA, Bluemke DA, McClelland R, Cushman M, Criqui MH, Polak JF, Lima JA.. Relation of leptin to left ventricular hypertrophy (from the multi-ethnic study of atherosclerosis). Am J Cardiol. 2013; 112:726–730
4. Klok MD, Jakobsdottir S, Drent ML.. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8:21–34
5. Tanai E, Frantz S.. Pathophysiology of heart failure. Compr Physiol. 2015; 6:187–214
6. Cheung BM, Kumana CR.. Natriuretic peptides – relevance in cardiovascular disease. JAMA. 1998; 280:1983–1984
7. Allison MA, Criqui MH, Maisel AS, Daniels LB, Roberts CK, Polak JF, Cushman M.. Adiponectin is independently associated with NT-probnp: the multi-ethnic study of atherosclerosis. Nutr Metab Cardiovasc Dis. 2015; 25:780–786
8. Bobbert P, Jenke A, Bobbert T, Kühl U, Rauch U, Lassner D, et al. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012; 14:1265–1275
9. Hall ME, Harmancey R, Stec DE.. Lean heart: role of leptin in cardiac hypertrophy and metabolism. World J Cardiol. 2015; 7:511–524
10. Krim SR, Vivo RP, Krim NR, Qian F, Cox M, Ventura H, et al. Racial/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from get with the guidelines-heart failure. JACC Heart Fail. 2013; 1:345–352
11. Daniels LB, Bhalla V, Clopton P, Hollander JE, Guss D, McCullough PA, et al. B-type natriuretic peptide (BNP) levels and ethnic disparities in perceived severity of heart failure: results from the rapid emergency department heart failure outpatient trial (REDHOT) multicenter study of BNP levels and emergency department decision making in patients presenting with shortness of breath. J Card Fail. 2006; 12:281–285
12. Drazner MH.. Left ventricular hypertrophy is more common in black than white hypertensives: is this news?. Hypertension. 2004; 43:1160–1161
13. Taylor HA Jr. The Jackson Heart Study: an overview. Ethn Dis. 2005; 154 Suppl 6S6–13
14. Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH, et al. A community-driven model of research participation: the Jackson Heart Study participant recruitment and retention study. Ethn Dis. 2003; 13:438–455
15. Carpenter MA, Crow R, Steffes M, Rock W, Heilbraun J, Evans G, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004; 328:131–144
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419
17. Bidulescu A, Liu J, Chen Z, Hickson DA, Musani SK, Samdarshi TE, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study. Front Public Health. 2013; 1:16
18. Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, et al. Association of adiponectin with left ventricular mass in blacks: the Jackson Heart Study. Circ Heart Fail. 2011; 4:747–753
19. Liu J, Fox CS, Hickson DA, May WL, Ding J, Carr JJ, Taylor HA.. Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diabetes Care. 2011; 34:341–346
20. Fox ER, Musani SK, Samdarshi TE, Taylor JK, Beard WL, Sarpong DF, et al. Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. J Am Heart Assoc. 2015; 4
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N.. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57:450–458
22. Fox ER, Musani SK, Bidulescu A, Nagarajarao HS, Samdarshi TE, Gebreab SY, et al. Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. Circulation. 2011; 124:1021–1027
23. Team RCR: A Language and Environment for Statistical Computing. 2019, Vienna, Austria: R Foundation for Statistical Computing
24. Wickham H.. ggplot2: Elegant Graphics for Data Analysis. 2016, New York: Springer-Verlag
25. Preedy VR, Hunter RJ.. Adipokines. 2011, Enfield, N.H. Boca Raton, FL: Science Publishers; Distributed by CRC Press
26. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257:79–83
27. Rojas E, Rodríguez-Molina D, Bolli P, Israili ZH, Faría J, Fidilio E, et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014; 16:463
28. Gruden G, Landi A, Bruno G.. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014; 37:2899–2908
29. Ohara T, Kim J, Asakura M, Asanuma H, Nakatani S, Hashimura K, et al. Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens Res. 2008; 31:825–831
30. Tengiz I, Turk UO, Alioglu E, Kirilmaz B, Tamer GS, Tuzun N, Ercan E.. The relationship between adiponectin, NT-pro-BNP and left ventricular ejection fraction in non-cachectic patients with systolic heart failure: an observational study. Anadolu Kardiyol Der. 2013; 13:221–226
31. Komaba H, Igaki N, Goto S, Yokota K, Takemoto T, Hirosue Y, Goto T.. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. Nephron Clin Pract. 2007; 107:c103–c108
32. Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Mogelvang R.. Cardio-adipose tissue cross-talk: relationship between adiponectin, plasma pro brain natriuretic peptide and incident heart failure. Eur J Heart Fail. 2014; 16:633–638
33. Volpe M.. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014; 176:630–639
34. Allison MA, Jenny NS, McClelland RL, Cushman M, Rifkin D.. The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. J Hum Hypertens. 2015; 29:127–133
35. Tonelli AR, Fares WH, Dakkak W, Rao Y, Zhou X, Dweik RA.. Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. Pulm Circ. 2017; 7:727–729
36. Cody RJ.. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol. 1997; 80:9J–14J
37. Weber M, Hamm C.. Role of B-type natriuretic peptide (BNP) and NT-probnp in clinical routine. Heart. 2006; 92:843–849
Keywords:

adiponectin; African Americans; brain natriuretic peptide; leptin

© 2020Wolters Kluwer Health Lippincott Williams Wilkins